Pregnant patients, who have undergone the use of artificial nutrition in the 15 days prior to inclusion in this study, patients allergic to any components of the diets used, with severe hyperglycemia(greater than 180mg/dl) or hypertriglyceridemia (greater than 400mg/dl), with previous gastrointestinal diseases (surgical resections, malabsorption syndromes, inflammatory bowel diseases, persistent paralytic ileus, upper gastrointestinal bleeding or severe acute pancreatitis), with neutropenia-defined immunosuppression states, myelodysplastic syndromes, congenital immunodeficiency, or Acquired Immunodeficiency Syndrome (AIDS), immunosuppressive therapies in the last 03 months, systemic chemotherapy in the last 03 months, autologous bone marrow transplantation in the last year, halogenic bone marrow transplantation in the last 02 years, or existence of graft versus host disease (DEVH), with advanced chronic diseases (Child-Pugh stage C, grade IV heart failure (NYHA), chronic functional stage lung failure IV, terminal degenerative neurological processes, neoplasms in remission or progression over treatment), with processes with short life expectancy including end-stage chronic kidney disease, with acute processes that determine small survival as shock of any etiology with multiple organ dysfunction refractory to therapy in the first 48h or post-resuscitation severe neurological damage within 72 hours will be excluded

Pregnant patients, who have undergone the use of artificial nutrition in the 15 days prior to inclusion in this study, patients allergic to any components of the diets used, with severe hyperglycemia(greater than 180mg/dl) or hypertriglyceridemia (greater than 400mg/dl), with previous gastrointestinal diseases (surgical resections, malabsorption syndromes, inflammatory bowel diseases, persistent paralytic ileus, upper gastrointestinal bleeding or severe acute pancreatitis), with neutropenia-defined immunosuppression states, myelodysplastic syndromes, congenital immunodeficiency, or Acquired Immunodeficiency Syndrome (AIDS), immunosuppressive therapies in the last 03 months, systemic chemotherapy in the last 03 months, autologous bone marrow transplantation in the last year, halogenic bone marrow transplantation in the last 02 years, or existence of graft versus host disease (DEVH), with advanced chronic diseases (Child-Pugh stage C, grade IV heart failure (NYHA), chronic functional stage lung failure IV, terminal degenerative neurological processes, neoplasms in remission or progression over treatment), with processes with short life expectancy including end-stage chronic kidney disease, with acute processes that determine small survival as shock of any etiology with multiple organ dysfunction refractory to therapy in the first 48h or post-resuscitation severe neurological damage within 72 hours will be excluded